Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ifosfamide.

M Zalupski1, L H Baker

  • 1Department of Medicine, Wayne State University School of Medicine, Detroit, MI 48201-1998.

Journal of the National Cancer Institute
|June 15, 1988
PubMed
Summary
This summary is machine-generated.

Ifosfamide, an alkylating agent, shows promise in treating soft tissue sarcoma and testicular cancer. Managing its urinary toxicity enables broader application in various malignant diseases, though further efficacy studies are needed.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma.

European journal of cancer (Oxford, England : 1990)·2024
Same author

VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA.

Annals of oncology : official journal of the European Society for Medical Oncology·2012
Same author

Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study.

Leukemia·2010
Same author

A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers.

Annals of oncology : official journal of the European Society for Medical Oncology·2010
Same author

A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as first-line treatment in patients with advanced biliary cancers.

Investigational new drugs·2007
Same author

A phase II study of carboplatin and paclitaxel in esophageal cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2004
Same journal

A novel classification of small bowel adenocarcinoma based on the hidden genome classifier: a multi-institutional study.

Journal of the National Cancer Institute·2026
Same journal

Response to Yu, Wang and Ge.

Journal of the National Cancer Institute·2026
Same journal

Re: Cardiovascular disease risk after radiotherapy and anthracycline-based chemotherapy for diffuse large B-cell lymphoma.

Journal of the National Cancer Institute·2026
Same journal

Welcome reduction of US cervical cancer rates despite state differences.

Journal of the National Cancer Institute·2026
Same journal

Adjuvant dual HER2 blockade along the HER2-ER axis in APHINITY.

Journal of the National Cancer Institute·2026
Same journal

Re: Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25).

Journal of the National Cancer Institute·2026
See all related articles

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Ifosfamide is an alkylating agent and a cyclophosphamide analog.
  • It has shown significant activity in treating soft tissue sarcoma and testicular carcinoma.
  • Urinary toxicity associated with ifosfamide therapy can be managed, allowing for wider clinical use.

Purpose of the Study:

  • To present a comprehensive review of preclinical data and clinical trials involving ifosfamide.
  • To assess the efficacy and application of ifosfamide in the treatment of malignant diseases.

Main Methods:

  • Review of preclinical data.
  • Analysis of clinical trial results.

Main Results:

  • Ifosfamide demonstrates significant activity in soft tissue sarcoma and testicular carcinoma.

Related Experiment Videos

  • Management of urinary toxicity has facilitated increased use of ifosfamide in combination therapies.
  • Preliminary results in various diseases are encouraging.

    • Conclusions:

    • Ifosfamide is an active agent in specific cancers like soft tissue sarcoma and testicular carcinoma.
    • Effective management of its toxicity is key to its broader application.
    • Further studies are required to definitively establish the efficacy of ifosfamide across a range of malignant diseases.